🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation

Recruitingn/aAges 18 Years - 74 YearsAllAssistance Publique - Hôpitaux de Paris
NCT05233605 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

ICU Patients admitted after ARDS due to COVID infection should be weaned from invasive mechanical ventilation as quickly as possible. 60% of ARDS patient after COVID infection admitted in ICU developp a delirium during mechanical ventilation weaning, serious event that can lead to death or acute and late complications since 30% of patients who had a delirium in ICU develop cognitive sequelae. Based on epidemiological arguments and mouse models, severe neuroinflammation is considered to be one of the physiopathological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine exhibits neuroprotective effects. In experimental models, dexmedetomidine reduces brain inflammation acting directly on the microglial phenotype. The role of this chronic neuroinflammatory condition on cognitive abilities and reserve begins to emerge in the lite

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patient (age ≥ 18 years at the time of inclusion) under 75 years old * COVID-19 infection documented by PCR test performed on a nasopharyngeal swab or from a bronchoalveolar sample * High affinity homozygous TPSO genotyping for \[18F\] -DPA-714 or heterozygous intermediate affinity for \[18F\] -DPA-714 * Patient who was hospitalized in intensive care for ARDS after COVID infection which required mechanical ventilation and deep sedation for at least 24 hours * Patient alive at 24 months (+ 24 months) after discharge from intensive care * Signature of informed consent * Patient affiliated to a National French social security system, excluding (French) State Medical Aid (SMA) For the group of patients exposed to dexmedetomidine: * Administration of dexmedetomidine for at least 24 hours during intensive care hospitalization For the group of patients not exposed to dexmedetomidine: * No administration of dexmedetomidine during intensive care hospitalization Exclusion Criteria: * Protected adult (under legal protection, guardianship or curatorship) * Pregnancy or breast-feeding * Contraindication to PET or MRI examination * Severe renal impairment (creatinine clearance \<30 mL / min) * Contraindication to the administration of the radiopharmaceutical agent \[18F\]-DPA-714 * Serious neurological history at admission to intensive care: * Stroke * Severe head trauma * Dementia with loss of autonomy
💊

What it tests

  • Not listed
📍

Where

1 site
Anesthesy department - Hôpital Pitié Salpêtrière
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy